Berkeley Capital Partners LLC Sells 739 Shares of AstraZeneca plc (NYSE:AZN)

Berkeley Capital Partners LLC reduced its stake in AstraZeneca plc (NYSE:AZN) by 3.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,176 shares of the company’s stock after selling 739 shares during the period. Berkeley Capital Partners LLC’s holdings in AstraZeneca were worth $1,006,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Advisor Partners LLC boosted its stake in AstraZeneca by 3.6% in the fourth quarter. Advisor Partners LLC now owns 24,879 shares of the company’s stock valued at $1,264,000 after acquiring an additional 872 shares in the last quarter. Mckinley Capital Management LLC Delaware boosted its stake in AstraZeneca by 25.2% in the fourth quarter. Mckinley Capital Management LLC Delaware now owns 54,318 shares of the company’s stock valued at $2,709,000 after acquiring an additional 10,947 shares in the last quarter. J.W. Cole Advisors Inc. acquired a new stake in AstraZeneca in the fourth quarter valued at approximately $246,000. Ballentine Partners LLC boosted its stake in AstraZeneca by 14.4% in the fourth quarter. Ballentine Partners LLC now owns 6,506 shares of the company’s stock valued at $324,000 after acquiring an additional 817 shares in the last quarter. Finally, Focused Wealth Management Inc boosted its stake in AstraZeneca by 28.2% in the fourth quarter. Focused Wealth Management Inc now owns 1,190 shares of the company’s stock valued at $59,000 after acquiring an additional 262 shares in the last quarter. Institutional investors and hedge funds own 17.45% of the company’s stock.

Several equities research analysts have weighed in on AZN shares. Zacks Investment Research downgraded shares of AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research note on Thursday, October 3rd. Liberum Capital reaffirmed a “hold” rating on shares of AstraZeneca in a report on Thursday, October 24th. Cowen reaffirmed an “outperform” rating and issued a $55.00 price target (up previously from $48.00) on shares of AstraZeneca in a report on Monday, December 2nd. Leerink Swann assumed coverage on shares of AstraZeneca in a report on Friday, November 22nd. They issued an “outperform” rating and a $57.00 price target for the company. Finally, ValuEngine cut shares of AstraZeneca from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 8th. Five research analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $50.35.

AstraZeneca stock opened at $49.28 on Friday. The company’s 50 day simple moving average is $49.74 and its 200-day simple moving average is $46.02. The company has a market capitalization of $129.30 billion, a price-to-earnings ratio of 60.10, a price-to-earnings-growth ratio of 1.49 and a beta of 0.46. AstraZeneca plc has a 1 year low of $35.30 and a 1 year high of $51.55. The company has a debt-to-equity ratio of 1.29, a quick ratio of 0.70 and a current ratio of 0.92.

AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.05. The business had revenue of $6.13 billion for the quarter, compared to the consensus estimate of $6.07 billion. AstraZeneca had a net margin of 8.42% and a return on equity of 38.63%. The business’s revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.71 EPS. Equities analysts expect that AstraZeneca plc will post 1.82 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: How to build a Fibonacci channel

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.